Search results
US FDA advisers to consider if new COVID shots should target JN.1 variant By Reuters
Investing.com· 2 days agoShares of Novavax (NASDAQ:NVAX) soared 11% in morning trade, after the documents were released. The...
Moderna wins second product approval with RSV vaccine
Morningstar· 5 days agoModerna Inc.'s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA < ...
Moderna wins second product approval with RSV vaccine
Market Watch· 5 days agoThe Food and Drug Administration approved the mRNA shot, mResvia, for adults 60 and older,...
US approves Moderna's RSV vaccine for older adults
Medical Xpress· 5 days agoThere are already two approved vaccines for those aged 60 and over, by GSK and Pfizer, both of which have been on the market since last year. "The FDA...
Pfizer's Options Frenzy: What You Need to Know - Pfizer (NYSE:PFE)
Benzinga· 6 days agoWhile it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal ...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Morningstar· 2 days agoPfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman ...
US FDA advisers to consider if new COVID shots should target JN.1 variant
Reuters via Yahoo News· 2 days agoShares of Novavax soared 11% in morning trade, after the documents were released. The company had...
US FDA advisers to consider if new COVID shots should target JN.1 variant
Colorado Springs Gazette· 2 days agoShares of Novavax soared 11% in morning trade, after the documents were released. The company had...
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks via Yahoo Finance· 2 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the...
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks· 3 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.